Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study

MLA

Menni, Cristina, et al. “Symptom Prevalence, Duration, and Risk of Hospital Admission in Individuals Infected with SARS-CoV-2 during Periods of Omicron and Delta Variant Dominance: A Prospective Observational Study from the ZOE COVID Study.” The Lancet, vol. 399, no. 10335, Apr. 2022, pp. 1618–24. EBSCOhost, https://doi.org/10.1016/S0140-6736(22)00327-0.

APA

Menni, C., Valdes, A. M., Polidori, L., Antonelli, M., Penamakuri, S., Nogal, A., Louca, P., May, A., Figueiredo, J. C., Hu, C., Molteni, E., Canas, L., Österdahl, M. F., Modat, M., Sudre, C. H., Fox, B., Hammers, A., Wolf, J., Capdevila, J., … Spector, T. D. (2022). Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. The Lancet, 399(10335), 1618–1624. https://doi.org/10.1016/S0140-6736(22)00327-0

Chicago

Menni, Cristina, Ana M Valdes, Lorenzo Polidori, Michela Antonelli, Satya Penamakuri, Ana Nogal, Panayiotis Louca, et al. 2022. “Symptom Prevalence, Duration, and Risk of Hospital Admission in Individuals Infected with SARS-CoV-2 during Periods of Omicron and Delta Variant Dominance: A Prospective Observational Study from the ZOE COVID Study.” The Lancet 399 (10335): 1618–24. doi:10.1016/S0140-6736(22)00327-0.